EOLS

Handel nachbörslich: 12.09 0.08 +0.67%

Evolus Inc (EOLS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Evolus Inc Stock (EOLS) Company Profile

Healthcare (1175)

(949) 284-4555

520 NEWPORT CENTER DRIVE, NEWPORT BEACH

@evolusaesthetic

Nächster Verdiensttermin

Neueste SEC-Einreichungen

EOLS's Discussions on Twitter

Vergleichen Sie EOLS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
EOLS Evolus Inc	12.01	719.17M	202.09M	-61.69M	-35.64M	-1.08
ZTS Zoetis Inc	158.06	68.50B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.38	47.71B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.63	46.12B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.39	18.55B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	298.70	13.40B	2.76B	1.11B	898.10M	22.77

Evolus Inc Stock (EOLS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-04-17	Eingeleitet	BTIG Research	Buy
2024-01-29	Hochstufung	Barclays	Equal Weight → Overweight
2022-06-23	Eingeleitet	Needham	Buy
2022-05-12	Hochstufung	Barclays	Underweight → Equal Weight
2022-01-20	Hochstufung	Truist	Hold → Buy
2021-05-06	Hochstufung	Mizuho	Neutral → Buy
2021-04-08	Bestätigt	H.C. Wainwright	Buy
2021-02-24	Herabstufung	Truist	Buy → Hold
2020-07-07	Herabstufung	Mizuho	Buy → Neutral
2020-02-06	Fortgesetzt	Mizuho	Buy
2019-11-26	Eingeleitet	SVB Leerink	Outperform
2019-09-05	Fortgesetzt	Mizuho	Buy
2019-06-28	Eingeleitet	Wells Fargo	Market Perform
2019-06-11	Eingeleitet	Barclays	Underweight
2019-03-20	Eingeleitet	SunTrust	Buy
2019-02-14	Eingeleitet	H.C. Wainwright	Buy
2019-01-29	Eingeleitet	Stifel	Buy

Alle ansehen

Evolus Inc Aktie (EOLS) Neueste Nachrichten

Finanzdaten der Evolus Inc-Aktie (EOLS)

Evolus Inc (EOLS)

Evolus Inc Stock (EOLS) Company Profile

Vergleichen Sie EOLS mit anderen Aktien

Evolus Inc Stock (EOLS) Upgrades & Downgrades

Evolus Inc Aktie (EOLS) Neueste Nachrichten

Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Evolus (EOLS) and Becton Dickinson (BDX) - The Globe and Mail

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance

When Will Evolus, Inc. (NASDAQ:EOLS) Breakeven? - simplywall.st

Evolus Inc (EOLS) Shares Gap Down to $11.115 on Apr 28 - GuruFocus

Midday Stock Roundup: FivePoint Rises on Earnings - Orange County Business Journal

Evolus to Report First Quarter Financial Results on May 7, 2025 - BioSpace

Evolus: Two-Product Aesthetics Company With A Competitive Edge (NASDAQ:EOLS) - Seeking Alpha

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | EOLS Stock News - GuruFocus

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Evolus announces commercial launch of Evolysse - MSN

BTIG Initiates Coverage of Evolus (EOLS) with Buy Recommendation - Nasdaq

BTIG Initiates Evolus at Buy With $21 Price Target - marketscreener.com

Evolus initiated with a Buy at BTIG - TipRanks

BTIG Initiates Coverage on Evolus (EOLS) with Optimistic Outlook | EOLS Stock News - GuruFocus

BTIG Initiates Coverage on Evolus (EOLS) with Optimistic Outlook - GuruFocus

Evolus Launches "Drop The F Word" To Redefine Aesthetic Injectables With Evolysse - Nasdaq

Evolus Announces Commercial Launch of Evolysse™ | EOLS Stock New - GuruFocus

Evolus Announces Commercial Launch of Evolysse™ - Yahoo Finance

Evolus Launches “Drop the F Word” Campaign in Advance of the Com - GuruFocus

Game-Changing Cold-X Technology: Evolus Revolutionizes Injectable Aesthetics with Natural Results - Stock Titan

Midday Stock Roundup: Evolus, ICU Medical down - Orange County Business Journal

H.C. Wainwright maintains Buy on Evolus stock with $27 target - Investing.com

H.C. Wainwright maintains Buy on Evolus stock with $27 target By Investing.com - Investing.com Canada

Evolus stock hits 52-week low at $9.22 amid market challenges - Investing.com Canada

Evolus stock hits 52-week low at $9.22 amid market challenges By Investing.com - Investing.com South Africa

Breaking Down Evolus: 8 Analysts Share Their Views - Benzinga

Investors Give Evolus, Inc. (NASDAQ:EOLS) Shares A 31% Hiding - simplywall.st

Evolus at Needham Conference: Strategic Launch of Evolisse By Investing.com - Investing.com Canada

Evolus at Needham Conference: Strategic Launch of Evolisse - Investing.com

Sandra Beaver: Evolus on Track to Hit $700M Revenue - Orange County Business Journal

Recent 11% pullback isn't enough to hurt long-term Evolus (NASDAQ:EOLS) shareholders, they're still up 170% over 5 years - simplywall.st

Evolus, Inc.: Navigating Financial Challenges Amidst Ongoing Losses and Market Uncertainty - MSN

Evolus CEO David Moatazedi sells $77,512 in stock By Investing.com - Investing.com India

Evolus CEO David Moatazedi sells $77,512 in stock - Investing.com Australia

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference - BioSpace

Evolus Inc (EOLS) Shares Down 4.54% on Mar 25 - GuruFocus

Investing in Evolus (NASDAQ:EOLS) five years ago would have delivered you a 216% gain - Yahoo

Evolus reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:17 pm EDT - MarketScreener

Evolus director David Moatazedi sells $1.37 million in stock By Investing.com - Investing.com Australia

Evolus Growth Continues: 14 New Employees Join as Company Strengthens Talent Pool - Stock Titan

Evolus to Participate in Canaccord Genuity’s 43rd Annual Growth Conference - Business Wire

Evolus executive Avelar Rui sells $369,867 in stock By Investing.com - Investing.com South Africa

Evolus CFO Sandra Beaver sells $119,242 in company stock By Investing.com - Investing.com South Africa

Evolus chief marketing officer sells $60,124 in common stock By Investing.com - Investing.com South Africa

Finanzdaten der Evolus Inc-Aktie (EOLS)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie EOLS